Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review - Takeaways - MDSpire

Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review

  • By

  • Xin Shen

  • Jiangnan Yang

  • Yang Du

  • Deyuan Fu

  • June 4, 2026

  • 0 min

Share

  • 1

    Primary triple-negative neuroendocrine breast carcinoma (NEBC) is a rare and aggressive subtype of breast cancer with limited treatment guidelines.

  • 2

    A 71-year-old woman with primary NEBC underwent curative mastectomy and received adjuvant chemotherapy combined with pembrolizumab.

  • 3

    The patient's treatment regimen included paclitaxel and cisplatin, administered alongside pembrolizumab, with manageable side effects.

  • 4

    At 12 months post-treatment, the patient remains disease-free, indicating potential efficacy of the combined therapy in NEBC.

  • 5

    This case contributes to the understanding of chemo-immunotherapy in primary NEBC, suggesting a need for further research in this area.

Original Source(s)

Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review

  • by Xin Shen, Jiangnan Yang, Yang Du, Deyuan Fu

  • June 4, 2026

Related Content

Development and validation of a machine learning-based risk prediction model for cancer-related fatigue in ovarian cancer patients

Global trends and emerging frontiers of large language models in cancer research

A multimodal ultrasound-based model combining tumor radiomics and axillary lymph node morphologic classification for predicting axillary nodal burden in breast cancer